文献速递糖尿病肥胖与代谢综合征

替尔泊肽改善2型糖尿病患者胰岛细胞功能与胰岛素敏感性标志物(SURPASS-2)

Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

SURPASS-2 3期试验的事后分析纳入1879例2型糖尿病患者,比较每周一次替尔泊肽(5、10、15 mg)与司美格鲁肽1 mg治疗40周的效果。替尔泊肽各剂量组HOMA2-B升幅(96.9%-120.4%)和HOMA2-IR降幅(15.5%-24.0%)均大于司美格鲁肽1 mg(分别为84.0%和5.1%)(P < .05)。在各基线HOMA2-B和HOMA2-IR四分位组内,替尔泊肽各剂量的HbA1c和体重降幅均大于司美格鲁肽。

要点

  • 替尔泊肽5、10、15 mg组HOMA2-B升幅96.9%-120.4%,大于司美格鲁肽1 mg组的84.0%(P < .05)。
  • 替尔泊肽各剂量组HOMA2-IR降幅15.5%-24.0%,大于司美格鲁肽1 mg组的5.1%(P < .05)。
  • 替尔泊肽10和15 mg组空腹C肽降幅5.2%-6.0%、空腹胰高血糖素降幅53.0%-55.3%,与司美格鲁肽1 mg组C肽升高3.3%、胰高血糖素降低47.7%相比有显著差异(P < .05)。

核心结论

  • 在此事后分析中,无论基线β细胞功能和胰岛素抵抗水平如何,替尔泊肽较司美格鲁肽的HbA1c改善和体重下降均一致且显著更高。

研究设计与样本

  • SURPASS-2 3期试验的事后分析,参与者随机接受每周皮下注射替尔泊肽或司美格鲁肽治疗40周。
  • 分析覆盖8个国家128个中心,共纳入1879例2型糖尿病患者。
  • 干预为每周一次替尔泊肽5、10、15 mg或司美格鲁肽1 mg。

主要发现

  • 第40周时,替尔泊肽5、10、15 mg组HOMA2-B升幅为96.9%-120.4%,大于司美格鲁肽1 mg组的84.0%(P < .05)。
  • 替尔泊肽各剂量组HOMA2-IR降幅为15.5%-24.0%,大于司美格鲁肽1 mg组的5.1%(P < .05)。
  • 替尔泊肽10和15 mg组空腹C肽降幅为5.2%-6.0%,司美格鲁肽1 mg组空腹C肽升高3.3%(P < .05)。
  • 替尔泊肽10和15 mg组空腹胰高血糖素降幅为53.0%-55.3%,司美格鲁肽1 mg组降幅为47.7%(P < .05)。
  • 在每个HOMA2-B和HOMA2-IR基线四分位组内,替尔泊肽各剂量的HbA1c和体重降幅均大于司美格鲁肽。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and β-cell function to a greater extent than comparators. OBJECTIVE: Explore changes in biomarkers of β-cell function and insulin sensitivity and in efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide. DESIGN: Post hoc analysis of SURPASS-2 phase 3 trial (participants randomly assigned to receive weekly subcutaneous tirzepatide or semaglutide for 40 weeks). SETTING: Post hoc analysis of 128 sites in 8 countries. PARTICIPANTS: A total of 1879 participants with type 2 diabetes. INTERVENTIONS: Once-weekly tirzepatide (5, 10, 15 mg) or semaglutide 1 mg. MAIN OUTCOMES MEASURES: Change in homeostatic model assessment indices for pancreatic β-cell function (HOMA2-B) and for insulin resistance (HOMA2-IR), fasting glucagon, fasting C-peptide, and fasting insulin. RESULTS: At week 40, a greater increase in HOMA2-B was seen with tirzepatide (5, 10, 15 mg) doses (96.9-120.4%) than with semaglutide 1 mg (84.0%) (P < .05). There was a greater reduction in HOMA2-IR with all doses of tirzepatide (15.5%-24.0%) than with semaglutide 1 mg (5.1%) (P < .05). Tirzepatide 10 and 15 mg resulted in a significant reduction in both fasting C-peptide (5.2%-6.0%) and fasting glucagon (53.0%-55.3%) compared with an increase of C-peptide (3.3%) and a reduction of glucagon (47.7%) with semaglutide 1 mg (P < .05). HbA1c and body weight reductions were greater with all tirzepatide doses than semaglutide within each HOMA2-B and HOMA2-IR baseline quartile. CONCLUSION: In this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline β-cell function and insulin resistance, compared with semaglutide.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024. PMID: 38252888. doi:10.1210/clinem/dgae038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。